重组人血管内皮抑制素联合DCF方案新辅助化疗治疗进展期胃癌患者提高手术根治率  

Preoperative neoadjuvant chemotherapy with recombinant human vascular endostatin and DCF regimen for advanced gastric cancer increases the rate of radical surgical resection

作　　者：曲兴龙[1] 柴宇啸[1] 王奕静[1] 韩毓[1] 张怡[1] 陶莉[2] 

机构地区：[1]复旦大学附属肿瘤医院闵行分院肿瘤外科,上海200240 [2]复旦大学附属肿瘤医院闵行分院化疗科,上海200240

出　　处：《肿瘤》2011年第8期765-767,共3页Tumor

基　　金：上海市闵行区自然科学研究课题资助项目(编号:2009mhz029)

摘　　要：目的:观察进展期胃癌患者接受重组人血管内皮抑制素联合DCF(多西他赛+顺铂+5-氟尿嘧啶)方案新辅助化疗后手术治疗的临床疗效、不良反应和术后并发症。方法:2009年9月—2011年2月60例进展期胃癌患者随机分为治疗组(30例)和对照组(30例)。治疗组新辅助化疗采用重组人血管内皮抑制素联合DCF方案,对照组新辅助化疗采用单纯DCF方案,均化疗2个周期。化疗后4周行手术治疗。结果:对照组的肿瘤切除率为83.3%(25/30)、根治性切除率为46.7%(14/30)、剖腹探查率为16.7%(5/30);治疗组的肿瘤切除率为93.3%(28/30)、根治性切除率为70.0%(21/30)、剖腹探查率为6.7%(2/30);两组比较差异均有统计学意义(P<0.05)。两组无手术死亡病例。不良反应差异无统计学意义。结论:对进展期胃癌患者行重组人血管内皮抑制素联合DCF方案新辅助化疗后手术治疗,是一种安全而有效的治疗方法,可以提高肿瘤切除率和手术根治率。Objective： To investigate the clinical efficacy, adverse reactions and postoperative complications of neoadjuvant chemotherapy of DCF regimen （cisplatin＋docetaxel＋5-fluorouracil） combined with recombinant human （Rh）-endostatin subsequentially with surgery in advanced gastric cancer. Methods： From September 2009 to February 2011, 60 cases of advanced gastric cancer were randomized into study group （n=30） and control group （n=30）. The therapeutic schedule of the study group was Rh-endostatin plus DCF regimen, and which of the control group was DCF regimen alone. The chemotherapy was repeated for two cycles. The operation was performed four weeks after chemotherapy. Results： In the control group, the rate of tumor resection was 83.3% （25/30）, the radical resection rate was 46.7% （14/30）, and the laparotomy rate was 16.7% （5/30）. In the study group, the rate of tumor resection was 93.3% （28/30）, the radical resection rate was 70.0% （21/30）, and the laparotomy rate was 6.7% （2/30）. There were no significant differences in the adverse reactions and the postoperative complications between the two groups. No mortality was observed. Conclusion： The neoadjuvant chemotherapy of DCF regimen combined with Rh-endostatin subsequentially with surgery in advanced gastric cancer is effective and safe. The tumor resection rate and the cure rate are both increased.

关 键 词：胃肿瘤 重组人血管内皮抑制素 新辅助化疗 外科手术 

分 类 号：R735.2[医药卫生—肿瘤]